Ipilimumab(Bristol Myers Squibb)은 HER2 표적 항체로, Advanced Hepatocellular Carcinoma (HCC) 영역에서 개발·상용화 중입니다. 작용기전: targeting the NF-κB/NLRP3/IL-1β pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 9% (ClinicalTrials.gov NCT03033576). PK: t½ 15.4 h. 차별점: novel case of clinical and biochemical recovery of ICI-D.
HER2
Advanced Hepatocellular Carcinoma (HCC)
Active
CAR T cell infusions showing promising clinical efficacy, signali
delivery
novel case of clinical and biochemical recovery of ICI-D
targeting the NF-κB/NLRP3/IL-1β pathway
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
apoptosis, ELISA for cytokine profiling (TNF-α, IL-1β, IL-6), and Western blot/qPCR for pathway analysis (NF-κB
PD-L1) expression
resistance to cancer immune checkpoint blockade
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Ipilimumab(Bristol Myers Squibb)은 HER2 표적 항체로, Advanced Hepatocellular Carcinoma (HCC) 영역에서 개발·상용화 중입니다. 작용기전: targeting the NF-κB/NLRP3/IL-1β pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 9% (ClinicalTrials.gov NCT03033576). PK: t½ 15.4 h. 차별점: novel case of clinical and biochemical recovery of ICI-D.
HER2
Advanced Hepatocellular Carcinoma (HCC)
Active
CAR T cell infusions showing promising clinical efficacy, signali
delivery
novel case of clinical and biochemical recovery of ICI-D
targeting the NF-κB/NLRP3/IL-1β pathway
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
apoptosis, ELISA for cytokine profiling (TNF-α, IL-1β, IL-6), and Western blot/qPCR for pathway analysis (NF-κB
PD-L1) expression
resistance to cancer immune checkpoint blockade
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.